561679: Phase II data

Top-line data from 145 evaluable female patients in a double-blind, U.S. Phase II trial showed that 350 mg daily GSK561679 missed the primary

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE